Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections: In vitro and in vivo studies

Chin Chuan Tsai, Chi Shiuan Lin, Chun Ru Hsu, Chiu Ming Chang, I. Wei Chang, Li Wei Lin, Chih Hsin Hung, Jiun Ling Wang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: No animal model studies have been conducted in which the efficacy of herbal compounds has been tested against multidrug-resistant Acinetobacter baumannii infections. Very few antibiotics are available for the treatment of pulmonary infections caused by extensively drug-resistant Acinetobacter baumannii (XDRAB). To find alternative treatments, traditional Chinese herbs were screened for their antimicrobial potential. Methods: The present study screened 30 herbs that are traditionally used in Taiwan and that are commonly prescribed for heat clearing and detoxification. The herbs with antibacterial activities were analysed by disc diffusion assays, time-kill assays and a murine lung infection model. Results: Of the 30 herbs tested, only Scutellaria barbata demonstrated 100% in vitro activity against XDRAB. Furthermore, we compared the antibacterial effect of the S. barbata extract with that of colistin, and the S. barbata extract showed better antibacterial effect. In the XDRAB pneumonia murine model, we compared the antimicrobial effects of the orally administered S. barbata extract (200 mg/kg, every 24 h), the intratracheally administered colistin (75,000 U/kg, every 12 h), and the control group. The bacterial load in the lungs of the treatment group that received the oral S. barbata extract showed a significant decrease in comparison to that in the lungs of the control group. In addition, histopathological examinations also revealed better resolution of perivascular, peribronchial, and alveolar inflammation in the oral S. barbata extract-treated group. Conclusions: Our in vitro and in vivo data from the animal model support the use of S. barbata as an alternate drug to treat XDRAB pulmonary infections. However, detailed animal studies and clinical trials are necessary to establish the clinical utility of S. barbata in treating XDRAB pulmonary infections.

Original languageEnglish
Article number96
JournalBMC Complementary and Alternative Medicine
Volume18
Issue number1
DOIs
Publication statusPublished - Mar 20 2018

Fingerprint

Scutellaria
Acinetobacter Infections
Acinetobacter baumannii
Lung
Pharmaceutical Preparations
Colistin
Infection
Animal Models
Control Groups
Bacterial Load
Taiwan
In Vitro Techniques
Pneumonia
Hot Temperature
Clinical Trials
Anti-Bacterial Agents
Inflammation

Keywords

  • Animal model
  • Disc diffusion method
  • Multidrug-resistant Acinetobacter baumannii
  • Scutellaria barbata
  • Time-kill curve

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections : In vitro and in vivo studies. / Tsai, Chin Chuan; Lin, Chi Shiuan; Hsu, Chun Ru; Chang, Chiu Ming; Chang, I. Wei; Lin, Li Wei; Hung, Chih Hsin; Wang, Jiun Ling.

In: BMC Complementary and Alternative Medicine, Vol. 18, No. 1, 96, 20.03.2018.

Research output: Contribution to journalArticle

Tsai, Chin Chuan ; Lin, Chi Shiuan ; Hsu, Chun Ru ; Chang, Chiu Ming ; Chang, I. Wei ; Lin, Li Wei ; Hung, Chih Hsin ; Wang, Jiun Ling. / Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections : In vitro and in vivo studies. In: BMC Complementary and Alternative Medicine. 2018 ; Vol. 18, No. 1.
@article{cbfa5abf87d040528beb7ae81e14b644,
title = "Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections: In vitro and in vivo studies",
abstract = "Background: No animal model studies have been conducted in which the efficacy of herbal compounds has been tested against multidrug-resistant Acinetobacter baumannii infections. Very few antibiotics are available for the treatment of pulmonary infections caused by extensively drug-resistant Acinetobacter baumannii (XDRAB). To find alternative treatments, traditional Chinese herbs were screened for their antimicrobial potential. Methods: The present study screened 30 herbs that are traditionally used in Taiwan and that are commonly prescribed for heat clearing and detoxification. The herbs with antibacterial activities were analysed by disc diffusion assays, time-kill assays and a murine lung infection model. Results: Of the 30 herbs tested, only Scutellaria barbata demonstrated 100{\%} in vitro activity against XDRAB. Furthermore, we compared the antibacterial effect of the S. barbata extract with that of colistin, and the S. barbata extract showed better antibacterial effect. In the XDRAB pneumonia murine model, we compared the antimicrobial effects of the orally administered S. barbata extract (200 mg/kg, every 24 h), the intratracheally administered colistin (75,000 U/kg, every 12 h), and the control group. The bacterial load in the lungs of the treatment group that received the oral S. barbata extract showed a significant decrease in comparison to that in the lungs of the control group. In addition, histopathological examinations also revealed better resolution of perivascular, peribronchial, and alveolar inflammation in the oral S. barbata extract-treated group. Conclusions: Our in vitro and in vivo data from the animal model support the use of S. barbata as an alternate drug to treat XDRAB pulmonary infections. However, detailed animal studies and clinical trials are necessary to establish the clinical utility of S. barbata in treating XDRAB pulmonary infections.",
keywords = "Animal model, Disc diffusion method, Multidrug-resistant Acinetobacter baumannii, Scutellaria barbata, Time-kill curve",
author = "Tsai, {Chin Chuan} and Lin, {Chi Shiuan} and Hsu, {Chun Ru} and Chang, {Chiu Ming} and Chang, {I. Wei} and Lin, {Li Wei} and Hung, {Chih Hsin} and Wang, {Jiun Ling}",
year = "2018",
month = "3",
day = "20",
doi = "10.1186/s12906-018-2151-7",
language = "English",
volume = "18",
journal = "BMC Complementary and Alternative Medicine",
issn = "1472-6882",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections

T2 - In vitro and in vivo studies

AU - Tsai, Chin Chuan

AU - Lin, Chi Shiuan

AU - Hsu, Chun Ru

AU - Chang, Chiu Ming

AU - Chang, I. Wei

AU - Lin, Li Wei

AU - Hung, Chih Hsin

AU - Wang, Jiun Ling

PY - 2018/3/20

Y1 - 2018/3/20

N2 - Background: No animal model studies have been conducted in which the efficacy of herbal compounds has been tested against multidrug-resistant Acinetobacter baumannii infections. Very few antibiotics are available for the treatment of pulmonary infections caused by extensively drug-resistant Acinetobacter baumannii (XDRAB). To find alternative treatments, traditional Chinese herbs were screened for their antimicrobial potential. Methods: The present study screened 30 herbs that are traditionally used in Taiwan and that are commonly prescribed for heat clearing and detoxification. The herbs with antibacterial activities were analysed by disc diffusion assays, time-kill assays and a murine lung infection model. Results: Of the 30 herbs tested, only Scutellaria barbata demonstrated 100% in vitro activity against XDRAB. Furthermore, we compared the antibacterial effect of the S. barbata extract with that of colistin, and the S. barbata extract showed better antibacterial effect. In the XDRAB pneumonia murine model, we compared the antimicrobial effects of the orally administered S. barbata extract (200 mg/kg, every 24 h), the intratracheally administered colistin (75,000 U/kg, every 12 h), and the control group. The bacterial load in the lungs of the treatment group that received the oral S. barbata extract showed a significant decrease in comparison to that in the lungs of the control group. In addition, histopathological examinations also revealed better resolution of perivascular, peribronchial, and alveolar inflammation in the oral S. barbata extract-treated group. Conclusions: Our in vitro and in vivo data from the animal model support the use of S. barbata as an alternate drug to treat XDRAB pulmonary infections. However, detailed animal studies and clinical trials are necessary to establish the clinical utility of S. barbata in treating XDRAB pulmonary infections.

AB - Background: No animal model studies have been conducted in which the efficacy of herbal compounds has been tested against multidrug-resistant Acinetobacter baumannii infections. Very few antibiotics are available for the treatment of pulmonary infections caused by extensively drug-resistant Acinetobacter baumannii (XDRAB). To find alternative treatments, traditional Chinese herbs were screened for their antimicrobial potential. Methods: The present study screened 30 herbs that are traditionally used in Taiwan and that are commonly prescribed for heat clearing and detoxification. The herbs with antibacterial activities were analysed by disc diffusion assays, time-kill assays and a murine lung infection model. Results: Of the 30 herbs tested, only Scutellaria barbata demonstrated 100% in vitro activity against XDRAB. Furthermore, we compared the antibacterial effect of the S. barbata extract with that of colistin, and the S. barbata extract showed better antibacterial effect. In the XDRAB pneumonia murine model, we compared the antimicrobial effects of the orally administered S. barbata extract (200 mg/kg, every 24 h), the intratracheally administered colistin (75,000 U/kg, every 12 h), and the control group. The bacterial load in the lungs of the treatment group that received the oral S. barbata extract showed a significant decrease in comparison to that in the lungs of the control group. In addition, histopathological examinations also revealed better resolution of perivascular, peribronchial, and alveolar inflammation in the oral S. barbata extract-treated group. Conclusions: Our in vitro and in vivo data from the animal model support the use of S. barbata as an alternate drug to treat XDRAB pulmonary infections. However, detailed animal studies and clinical trials are necessary to establish the clinical utility of S. barbata in treating XDRAB pulmonary infections.

KW - Animal model

KW - Disc diffusion method

KW - Multidrug-resistant Acinetobacter baumannii

KW - Scutellaria barbata

KW - Time-kill curve

UR - http://www.scopus.com/inward/record.url?scp=85044188773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044188773&partnerID=8YFLogxK

U2 - 10.1186/s12906-018-2151-7

DO - 10.1186/s12906-018-2151-7

M3 - Article

C2 - 29554903

AN - SCOPUS:85044188773

VL - 18

JO - BMC Complementary and Alternative Medicine

JF - BMC Complementary and Alternative Medicine

SN - 1472-6882

IS - 1

M1 - 96

ER -